Cargando…

Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer

Epidermal growth factor receptor (EGFR) is a pro-tumorigenic receptor tyrosine kinase that facilitates growth for cancer cells that overexpress the receptor. Monoclonal anti-EGFR antibody Cetuximab (CTX) provides significant clinical benefit in patients with head and neck squamous cell carcinoma (HN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nair, Sindhu, Trummell, Hoa Q., Rajbhandari, Rajani, Thudi, Nanda K., Nozell, Susan E., Warram, Jason M., Willey, Christopher D., Yang, Eddy S., Placzek, William J., Bonner, James A., Bredel, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028269/ https://www.ncbi.nlm.nih.gov/pubmed/32069320 http://dx.doi.org/10.1371/journal.pone.0229077

Ejemplares similares

Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 Inhibition
por: Bonner, James A., et al.
Publicado: (2015)

EGFR Mutations in Head and Neck Squamous Cell Carcinoma
por: Nair, Sindhu, et al.
Publicado: (2022)

Cetuximab Augments Cytotoxicity with Poly (ADP-Ribose) Polymerase Inhibition in Head and Neck Cancer
por: Nowsheen, Somaira, et al.
Publicado: (2011)

Ectodomain shedding of EGFR ligands serves as an activation readout for TRP channels
por: Tatsumi, Manae, et al.
Publicado: (2023)

DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma
por: Weaver, Alice N., et al.
Publicado: (2015)

Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signaling
por: Shen, Hongxing, et al.
Publicado: (2022)

Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands
por: Sahin, Umut, et al.
Publicado: (2004)

STAT4 controls GM-CSF production by both Th1 and Th17 cells during EAE
por: McWilliams, Ian L., et al.
Publicado: (2015)

Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI
por: Yonesaka, Kimio, et al.
Publicado: (2019)

Ligand binding and dynamics of the monomeric epidermal growth factor receptor ectodomain
por: Loeffler, Hannes H, et al.
Publicado: (2013)

ADAM17 is essential for ectodomain shedding of the EGF‐receptor ligand amphiregulin
por: Hosur, Vishnu, et al.
Publicado: (2018)

Cryo-EM structure of the complete and ligand-saturated insulin receptor ectodomain
por: Gutmann, Theresia, et al.
Publicado: (2019)

Combining PARP and DNA-PK Inhibitors With Irradiation Inhibits HPV-Negative Head and Neck Cancer Squamous Carcinoma Growth
por: Zeng, Ling, et al.
Publicado: (2020)

Regulation of Angiopoietin Signalling by Soluble Tie2 Ectodomain and Engineered Ligand Trap
por: Alawo, Deborah O. A., et al.
Publicado: (2017)

EpCAM ectodomain EpEX is a ligand of EGFR that counteracts EGF-mediated epithelial-mesenchymal transition through modulation of phospho-ERK1/2 in head and neck cancers
por: Pan, Min, et al.
Publicado: (2018)

Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy (†)
por: Sihver, Wiebke, et al.
Publicado: (2014)

Engineering an Enhanced EGFR Engager: Humanization of Cetuximab for Improved Developability
por: Goulet, Dennis R., et al.
Publicado: (2022)

An ErbB Lineage Co-Regulon Harbors Potentially Co-Druggable Targets for Multimodal Precision Therapy in Head and Neck Squamous Cell Carcinoma
por: Bredel, Markus, et al.
Publicado: (2022)

EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab
por: Kono, Scott A., et al.
Publicado: (2012)

TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells
por: Ming Lim, Chwee, et al.
Publicado: (2013)

FOXD1 Regulates the Sensitivity of Cetuximab by Regulating the Expression of EGFR in Head and Neck Squamous Cell Cancer
por: Mu, Lan, et al.
Publicado: (2022)

EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma
por: Chaudhary, Ritu, et al.
Publicado: (2023)

Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family
por: Arkhipov, Anton, et al.
Publicado: (2013)

The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer
por: Khelwatty, Said, et al.
Publicado: (2016)

Loss of tumor suppressive microRNA-31 enhances TRADD/NF-κB signaling in glioblastoma
por: Rajbhandari, Rajani, et al.
Publicado: (2015)

EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab
por: CHIADINI, ELISA, et al.
Publicado: (2015)

EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer
por: Cserepes, Mihály, et al.
Publicado: (2022)

Retracted: FOXD1 Regulates the Sensitivity of Cetuximab by Regulating the Expression of EGFR in Head and Neck Squamous Cell Cancer
por: Healthcare Engineering, Journal of
Publicado: (2023)

A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells
por: Landi, Nicola, et al.
Publicado: (2023)

Ligand-Independent EGFR Activation by Anchorage-Stimulated Src Promotes Cancer Cell Proliferation and Cetuximab Resistance via ErbB3 Phosphorylation
por: Nozaki, Masami, et al.
Publicado: (2019)

Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
por: Ribeiro Gomes, Jéssica, et al.
Publicado: (2015)

Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope
por: Makabe, Koki, et al.
Publicado: (2021)

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
por: Cappuzzo, F, et al.
Publicado: (2008)

Antitumor effect of cetuximab in combination with S-1 in EGFR-amplified gastric cancer cells
por: FUKUDA, KAZUMASA, et al.
Publicado: (2011)

A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy
por: Zhang, Lianhai, et al.
Publicado: (2013)

NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer
por: Yang, Guang, et al.
Publicado: (2021)

Myristoylated alanine-rich C-kinase substrate effector domain phosphorylation regulates the growth and radiation sensitization of glioblastoma
por: Eustace, Nicholas J., et al.
Publicado: (2019)

Ectodomain Shedding of Epidermal Growth Factor Receptor Ligands Is Required for Keratinocyte Migration in Cutaneous Wound Healing
por: Tokumaru, Sho, et al.
Publicado: (2000)

Molecular design of the γδT cell receptor ectodomain encodes biologically fit ligand recognition in the absence of mechanosensing
por: Mallis, Robert J., et al.
Publicado: (2021)

Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers
por: Gao, Rebecca W., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qo232bq1uvs8vk8g8vbottogsj